Technologies pour la Santé / Technologies for Health (TecSan)
The Federate Research (FR) “Technologies for Health” combines the scientific activity of 11 partners (see organigram). The research activity of these various partners encompasses several fields relevant to “Technologies for Health”, from fundamental research to clinical development,. The technical supports of the various partners of the FR ensure a continuum of research, within the framework of a scientific program, from cellular and molecular aspects to the clinic.
This FR is in close interaction with the other FRs of the University of Bordeaux that are more disciplinary orientated, such as “Public Health”, “Neuroscience”, or “Translational Biology and Medicine”. The FR is also closely associated to the Teaching Hospital of Bordeaux (CHU de Bordeaux) and its various clinical poles, as well as the clinical research platforms dedicated to these operations such as the Centre for Clinical Investigation (CIC). Chemists, biologists, biotechnologists, biophysicists, physiologists, pharmacologists, specialists of in vivo imaging, physicians, and surgeons associated within the FR commit themselves to promoting multidisciplinary an d translational approaches in 4 main research axes that are described below.
The valorization activity of the FR and its ability to attract new partners are facilitated by the integration within the FR of facilities dedicated to start-up companies.
- Université de Bordeaux
More specifically, the FRS develops a focused scientific program, organized into four major axes covering the major domains of “Technologies for Health”.
These axes are: 1. Molecules and targets of therapeutic or diagnostic interest; 2. Bioengineering and nanotechnologies; 3. Bio-Imaging; 4. Interventional techniques and assistance to the patient. These axes proceed by the integration of the experimental and technological assets of the various partners.
- The axis “Molecules and targets of therapeutic or diagnostic interest” focuses on the identification of new molecules or targets of interest ranging from complex nucleic acids to natural or synthetic polymers as well as natural or synthetic small molecules. Emphasis is put on strategies and techniques aiming at improving the effectiveness of drug targeting, bioproduction, delivery, and vectorization, as well as on evaluation of new formulations of existing drugs, optimization of clinical treatment or the detection of counterfeit drugs. The development of compounds contributing to bio- or nano-devices or aimed at treating diseases that currently lack of specific treatment (e.g. chronic respiratory diseases) is also a major goal. In this axis, we will also focus on the vascular network as a potential target for many diseases and a door for systemic treatment of ischemic diseases.
- The axis “Bioengineering and nanotechnologies” aims at designing new products (in concert with the above mentioned axis “Molecules and targets of therapeutic or diagnostic interest”); this axis investigates the self-assembly of amphiphilic molecules into supramolecular structures and nano-systems and nano-particles for drug delivery, cell imaging, cell tracking and tissue engineering.
These topics are likely to generate clinical applications in the fields of cancer, bone diseases, biocompatibility, bioactivity, and inflammation in the context of tissue regeneration.. This axis also emphasizes the development of nano-systems for bio-imaging (mostly by nuclear magnetic resonance) for diagnostic and therapeutic purposes, with specific applications in the domains of cancer, central nervous system diseases or atherosclerosis. The objectives are to develop new strategies likely to give access to early diagnosis and to improve follow-up. These projects are partially developed within the framework of the laboratory of excellence AMADEUS (Advanced Materials by Design).
- The axis “Bio-Imaging” is transversal. The main purpose of the in vivo imaging techniques developed here is to understand living systems and thus this axis also contributes to the field of Systems Biology. By early identification of pathological dysfunctions, bio-imaging plays a key role in the development of new diagnostic, follow-up, and prognostic strategies. It is an essential partner for the development of new minimally invasive therapeutic strategies like thermotherapy. This axis takes advantage of a high quality methodological and technological environment, particularly in the field of nuclear magnetic resonance, which will gain further structuration in the context of the Laboratory of Excellence “TRAIL” (Translational research and Advanced Imaging Laboratory) with strong interactions with all of the other axes of the FR. In addition, in the same field, the “Institut Hospitalo-Universitaire” LIRYC is a multidisciplinary research, clinical and teaching Institute gathering world competencies in cardiology, bio-imaging, signal processing and modeling on a single platform to understand the complexity of electrical cardiac diseases.
- The axis “Interventional techniques and assistance to the patient” focuses on the development of MRI thermometry for therapeutic purposes (in concert with the axis “Bio-Imaging”) with immediate applications in the domain of cancer or interventional rythmology. A series of projects including i) development of new electrical therapies and implantable devices for heart failure as well as new strategies for the prevention and treatment of sudden death; ii) development of new systems for regulated and retrocontroled in vivo insulin delivery; iii) use of the femtosecond laser for the treatment of presbyopia; iv)in vivo study of new magnetic resonance imaging markers of multiple sclerosis in relation with cognitive alterations are currently developed. In all cases, the main goal is to minimize the invasive character of treatments, while increasing success rate and decreasing adverse effects. All the projects closely associate basic research, clinical research and industry. Some of these projects also benefit from the strong support and environment of the Institute LIRYC.
Structures / Laboratories of FR TecSan
- Plateforme technologique d'innovation biomédicale
GIS CHU-UB (Directeur : Pierre Dos Santos)
- Institut de BioImagerie (IBIO)
CNRSCentre national de la recherche scientifique UMS 3428 CHU-UBS(Directeur : Vincent Dousset)
- Institut Européen de Chimie et Biologie
CNRSCentre national de la recherche scientifique UMS 3033 - InsermInstitut national de la santé et de la recherche médicale - UB1 - UBS (Directeur : Jean Louis Mergny)
- Centre de Résonance Magnétique des Systèmes Biologiques
CNRSCentre national de la recherche scientifique UMR 5536-UB (Directeur : Jean-Michel Franconi)
- ARN : Régulations Naturelle et Artificielle ARNA
U869 InsermInstitut national de la santé et de la recherche médicale - UB (Directeur : Jean-Louis Mergny)
- CRCTB : Centre de recherche cardio-thoracique de Bordeaux
U1045 InsermInstitut national de la santé et de la recherche médicale - UB (Directeur R. Marthan)
- Adaptation Cardiovasculaire à l’Ischémie
U1034 InsermInstitut national de la santé et de la recherche médicale - UB (Directeur Th. Coufinhal)
- Neuroinflammation : Imagerie et Thérapie de la Sclérose en Plaques
U1049 InsermInstitut national de la santé et de la recherche médicale - UB (Directeur : Klaus Pétry)
- Bioingénierie tissulaire
U1026 InsermInstitut national de la santé et de la recherche médicale - UB (Directeur : Joëlle Vilamitjana Amédée)
- Biotechnologie des Protéines Recombinantes à Visée Santé
EA 4135 – IPB (Directeur : Bertrand Garbay)
- Développements Analytiques et Pharmaceutiques appliqués aux Maladies Négligées et aux Contrefaçons
EA – UB (Directeur : Karen Gaudin)
146, rue Léo Saignat, Université de Bordeaux
Campus Bordeaux Carreire
33076 Bordeaux cedex
Tél. 05 57 57 14 88
Fax. 05 56 90 05 17